Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Notes Payables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Notes Payables for 3 consecutive years, with $105161.0 as the latest value for Q4 2025.

  • Quarterly Notes Payables fell 38.74% to $105161.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105161.0 through Dec 2025, down 38.74% year-over-year, with the annual reading at $105161.0 for FY2025, 38.74% down from the prior year.
  • Notes Payables for Q4 2025 was $105161.0 at bioAffinity Technologies, down from $136396.0 in the prior quarter.
  • The five-year high for Notes Payables was $325000.0 in Q3 2022, with the low at $4106.0 in Q2 2024.
  • Average Notes Payables over 3 years is $127979.0, with a median of $105161.0 recorded in 2025.
  • Peak annual rise in Notes Payables hit 2135.72% in 2025, while the deepest fall reached 48.93% in 2025.
  • Over 3 years, Notes Payables stood at $325000.0 in 2022, then crashed by 47.18% to $171669.0 in 2024, then tumbled by 38.74% to $105161.0 in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $105161.0, $136396.0, and $32946.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.